Welcome to the Mass General Brigham Innovation Board Candidates page. Below the gallery of featured leaders is a sortable database with real-time search function to identify suitable leaders for industry.
Browse the board candidates below. You can sort each column and real-time search by specialty, expertise, etc.
Fill out the contact form to request an introduction.
| Last | First | Credential | Institution | Title | Faculty Appointment | Specialty | Areas of Expertise | Biography | Statement | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akam | Eman | PhD | MGH | Instructor in Medicine | Cardiology | Molecular imaging of fibrogenesis, collagen cross-linking in cardiac regeneration, | Dr. Eman Akam is an investigator at the Massachusetts General Hospital Cardiology Division and an Instructor in Medicine at the Cardiovascular Research Center. Dr. Akam received her PhD in Chemistry from the University of Arizona and completed her postdoctoral training with professor Peter Caravan at the Martinos Center for Biomedical Imaging at MGH. Dr. Akam’s research focuses on development of imaging tools that can inform on molecular mechanisms of fibrotic heart and lung diseases. Additionally, Dr. Akam is passionate about mentoring, outreach, and the advancement and equal representation of historically marginalized communities in STEM fields. Dr. Akam is the recipient of the New England Educational Opportunity Association (NEOA) 2019 Rising Star award, and the co-founder and Director of the Melanated and Dedicated (MaD) Scientist outreach program. | ||||||||||||||||||
| Ambrosio | Fabrisia | PhD, MPT | SRH | Atlantic Charter Director of the Discovery Center for Musculoskeletal Recovery at the Schoen Adams Research Institute | Associate Professor | Physical Medicine and Rehabilitation | Aging Rehabilitation Regenerative Medicine Tissue Engineering | Fabrisia Ambrosio, PhD, is the Atlantic Charter Director of the Discovery Center for Musculoskeletal Recovery at the Schoen Adams Research Institute. She is also a faculty member in the Department of Physical Medicine & Rehabilitation at Harvard Medical School. Dr. Ambrosio’s research has the long-term goal of developing innovative approaches to improve skeletal muscle healing and functional recovery. Her translationally-oriented laboratory investigates underlying mechanisms by which mechanical signals can be used to enhance endogenous and/or donor stem cell function after injury or in the setting of disease. Dr. Ambrosio has published and recorded several educational modules on the topic of Regenerative Rehabilitation—the integration of regenerative medicine with rehabilitation science—and has assumed international leadership roles in several work group efforts to promote the field. She is the lead director of the Alliance for Regenerative Rehabilitation Research & Training (AR3T), an NIH-funded center that supports the expansion of scientific knowledge, expertise, and methodologies across the domains of rehabilitation science and regenerative medicine. Dr. Ambrosio is also the Founding Course Director of the Annual International Symposium on Regenerative Rehabilitation and the Founding Director of the International Consortium for Regenerative Rehabilitation, which includes 16 partnering institutions representing North America, Europe, and Asia. In 2022, she was inducted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. | |||||||||||||||||
| Anderson | Ana | PhD | BH | Associate Scientist, Neurology | Associate Professor | Neurology | Autoimmunity Immuno-Oncology Clinical Translation | Ana Anderson, PhD, is the Albert H. Coons Associate Professor of Neurology at Harvard Medical School, Scientist at the Brigham and Women’s Hospital, Institute Member of the Broad Institute of MIT and Harvard, Core Faculty of the Evergrande Center for Immunologic Diseases, and Co-Chair of the Infectious and Immunologic Diseases Program at the Brigham Research Institute. Anderson works in the field of cancer immunology, specifically on the regulation of the anti-tumor T cell response. Her laboratory identified the coinhibitory molecule Tim-3 as a key regulator of T cell dysfunction in cancer and has identified gene programs associated with activated, dysfunctional, and stem-like CD8+ T cell states in cancer. Prior to working in the field of cancer immunology, Anderson worked in the field of autoimmunity. She has published over 50 original papers, 19 reviews, and 5 book chapters. Anderson is on the editorial board for OncoImmunology, Cellular Immunology, and The Journal for Immunotherapy of Cancer. She currently serves on the scientific advisory boards for the Center for Immuno-Oncology at the Dana Farber Cancer Institute, Tizona Therapeutics, Trishula Therapeutics, Compass Therapeutics, Zumutor Biologics, and ImmuneOncia and is a consultant for iTeos Therapeutics and Larkspur Biosciences. She obtained her BS in Microbiology and Immunology from the University of Miami, where she graduated summa cum laude, and her PhD in Immunology from Harvard University. During her Ph.D. she was a fellow of the Howard Hughes Medical Institute. | I am currently the Albert H Coons Associate Professor of Neurology in the Field of Immunologic diseases. I am an Immunologist with expertise in autoimmune disease and cancer. I am inventor on multiple patents some of which have formed the basis for start-up companies. I have been fortunate to serve on multiple scientific advisory boards for startup biotech companies in the immune-oncology space and see the development of therapeutics go all the way into clinical trials. I am passionate about how the power of the immune system is being harnessed to make a difference in patient’s lives and how high throughput technologies have accelerated biological discovery. | ||||||||||||||||
| Artzi | Natalie | PhD | BH | Assistant Professor at the Department of Medicine, Division of Engineering in Medicine, | Assistant Professor | Biomedical Engineering | Drug delivery Gene therapy Nanomedicine Immunotherapy Cancer Infectious diseases Tissue engineering | Dr. Artzi is an Assistant Professor at the Department of Medicine, Division of Engineering in Medicine, Brigham and Women’s Hospital, Harvard medical School. She is a Principal Research Scientist at MIT and an Associate Member of the Broad Institute of Harvard and MIT. She completed her postdoctoral studies at MIT focusing on studying tissue:biomaterial interactions and designing smart biomaterials for therapy and diagnosis applications. Dr. Artzi is the recipient of multiple grants and awards, including the inaugural rising star Kabiller award in nanotechnology and nanomedicine, One Brave Idea award from Google Verily, American Heart Association and AstraZeneca , Stepping Strong Innovator Award and Breakthrough Award, Controlled Release Society Young Investigator Award, Bright Futures Prize, and the Massachusetts Life Science Center for women entrepreneurs. Currently, Dr. Artzi directs multiple research venues aiming to integrate science, engineering and medicine to rationally design personalized materials to improve human health, and has co-founded a startup company, BioDevek, which develops the next-generation biomaterials to improve outcomes following internal surgeries. | It is my passion and life mission to develop new technologies to the clinic for the betterment of human lives. As biomaterials science represents the next frontier in medical therapeutics, my research seeks to enhance the understanding of tissue-material interactions under specific environments and applications. We develop biologically-informed material platforms that can sense the environment, enhance tissue repair, provide the right therapy, and report on tissue state. Using a library of nanoparticle-based materials we developed for systemic delivery, as well as adhesive hydrogels and microneedle patches, for local and transdermal delivery, respectively, we can begin to answer basic questions such as what is the optimal target site for specific therapies as a function of their mechanism of action, what is the best way to deliver the therapy and the optimal release profile, as well as what is the best timing and order of therapy—all of which will help unravel basic immunobiological mechanisms, enhance specific cell uptake, and enhance therapy efficacy. | ||||||||||||||||
| Basgoz | Nesli | MD | MGH | Associate Chief, Infectious Disease | Associate Professor | Infectious Disease | Nesli Basgoz, MD, is the Associate Chief and Clinical Director of the Infectious Disease Division at Massachusetts General Hospital. She is an Associate Professor at Harvard Medical School, in the Clinical Expertise and Innovation track. She is an active clinician, maintaining a large clinical practice in HIV Primary Care and in consultative Infectious Disease. In 2019, she became the inaugural incumbent of the first MGH Master Clinician Endowed Chair. Basgoz also has a major role in medical education, teaching and mentoring medical students, residents and fellows. She is the Chief of the James Jackson Firm in the Department of Medicine, the first woman selected for this role. Basgoz has served on the MGH and Partners Healthcare Board of Trustees and on the Boards of Forest Laboratories and Allergan LLC. | ||||||||||||||||||
| Bertagnolli | Monica | MD | BH | Associate Surgeon | Professor | Surgical Oncology | Surgical Oncology Clinical Trials Health Information Technology | Monica Bertagnolli, MD, has been a member of the Board of Directors of ASCO from 2007-2011 and 2016-2021, and has been chair of the Board since 2018. She currently serves on the Board of Directors of the American Cancer Society, Natera, Inc., and Leap Therapeutics. She is also the group chair of the Alliance for Clinical Trials in Oncology, president of the Alliance for Clinical Trials in Oncology Foundation, and CEO of Alliance Foundation Trials, LLC. | |||||||||||||||||
| Borg-Stein | Joanne | MD | NWH | Chief, Physical Medicine and Rehabilitation | Associate Professor | Physical Medicine and Rehabilitation | Regernative Sports Medicine Osteoarthritis and Musculoskeletal Disorders | Joanne Borg-Stein, MD, is an associate professor of physical medicine and rehabilitation at Harvard Medical School and is the associate chair for Sports and Musculoskeletal Rehabilitation for the Harvard Department of Physical Medicine and Rehabilitation/Spaulding Rehabilitation Network. She is the medical director of the Spaulding- Wellesley Rehabilitation Center. She is chief of physical medicine and rehabilitation at Mass General Brigham/Newton- Wellesley Hospital. Borg-Stein serves as team physician for varsity athletics at Wellesley College and associate director of the Sports Medicine Fellowship at Spaulding Rehabilitation Hospital/Harvard Medical School. A major area of clinical and research focus in regenerative injection therapies for osteoarthritis and sports injuries. | Orthobiologic / regenerative medicine treatments for sports injuries and osteoarthritis. These include: platelet rich plasma and cell therapies: bone marrow aspirate concentrate and micronized fat transfer among others. | ||||||||||||||||
| Breakefield | Xandra | PhD | MGH | Geneticist | Professor | Genetics Neurology | Neurological Disorders Gene-based Therapies | Xandra Breakefield, PhD, is a research scientist with a strong background in molecular genetics and neuroscience. She has focused on: identification of neurologic disease genes, gene therapy for neurologic diseases; and the role of extracellular vesicles (EVs) in cell-to-cell communication and tumor progression. She has published over 500 scientific articles and has received continuous support from the National Institutes of Health in the USA for her research over a 40-year period. She did her undergraduate work at Wilson College and her graduate work in Microbial Genetics at Georgetown University. She was a Postdoctoral Fellow with Nobel Prize winner, Dr. Marshall Nirenberg at the NIH. She was appointed an Assistant Professor in the first Department of Human Genetics in the USA at Yale Medical School in 1974, and moved in 1984 to Harvard Medical School and Massachusetts General Hospital. She is currently Professor of Neurology in the Neuroscience Program at Harvard Medical School and Geneticist in the Neurology and Radiology Services at Massachusetts General Hospital. Breakefield has received a number of awards for her work, including a McKnight Foundation Neuroscience Development Award, two Javits Neuroscience Investigator Awards, the Society for Neuroscience Mika Salpeter Lifetime Achievement Award, and the Harvard Medical School William Silen Lifetime Achievement Mentoring Award. She is a current recipient of an Outstanding Investigator Award from the National Cancer Institute, a member of the American Academy of Arts and Sciences, and past president of the American Society of Gene and Cell Therapy. | I am a PhD Geneticist at MGH and Professor of Neurology at HMS. I am particularly interested in gene therapy for neurologic diseases and am very excited about our new extracellular vesicle (exosome) delivery system which provides biologic vehicles for simultaneous and short term delivery of protein, RNA and DNA which should be ideal for gene editing in vivo. | ||||||||||||||||
| Britton | O'Neil | MD | MGB | Senior VP, Operations and Associate Chief Operating Officer | Instructor | Operations | Clinical Operations Medical Education and Training Health Information Technology | O’Neil Britton, MD, joined Massachusetts General Hospital (MGH) in September 2016 as Chief Medical Officer and Senior Vice President. He provides administrative oversight of the departments of Pathology, Radiology, Dermatology, Pharmacy, Biomedical Engineering, the Center for Diversity, Equity, and Inclusion, the Center for Global Health, the Executive Committee on Teaching and Education, the Learning Laboratory/Center for Medical Simulation, physician professionalism and peer support, and the Medical Staff Office. Britton also continues to see patients and teach and mentor house-officers and students in the role of a hospitalist at MGH. Previously, he was the Chief Health Information Officer for Partners Healthcare, where he provided clinical, academic and administrative leadership in the development, implementation and operational advancement of Partners eCare, an initiative to implement an integrated health record across Partners HealthCare. This initiative fundamentally changed the delivery of healthcare through digitization of the electronic medical record and its associated data bases across the Mass General Brigham (MGB) Healthcare System. Before joining MGB in 2012, Britton served as Chief Medical Officer and Vice President of Professional Services at Brigham and Women’s Faulkner Hospital, as well as Vice Chair of Medicine at Brigham and Women’s Hospital. From 2005-2007, he served as the Medical Director of Horizon Blue Cross Blue Shield of New York, where he oversaw their medical management, appeals, credentialing/enrollment, and the complex case management units. Britton was born in Kingston, Jamaica and immigrated to New York as a teenager. He attended City College of New York and then Rutgers New Jersey Medical School. He also completed the Deland Fellowship, an administrative fellowship in healthcare management at Brigham and Women’s Hospital. | |||||||||||||||||
| Carter | Jocelyn | MD, MPH | MGH | Director, MGH Community CAre Transitions (C-CAT) Initiative +/- Director, Division of General Internal Medicine Research Equity | Professor | Medicine | Jocelyn Carter is an esteemed physician-scientist and expert in clinical and translational medicine, research methodologies and design, implementation science, and healthcare-industry integration leadership. She has extensive knowledge in the patient-provider interface inclusive of key frameworks, barriers, and facilitators to problem-solve for patient and provider-based pain points. With a mobile first approach that targets specific disease cohorts and the clinical teams that care for them, Jocelyn has partnered with numerous companies (e.g., CareConnect, Biofourmis, FreMon Scientific, MiCORE, Kinesis, Stel) and has critical knowledge of products and devices as well as service programming dedicated to pursuing these markets. As such, Jocelyn has extensive exposure to clinical development and product framing for market transformation as companies enter into FDA dialogues. This includes solving for barriers related to commercialization and identification of target markets. She has also advised companies in critical phases of clinical validation and commercial growth. Her close partnerships with technology and healthcare leaders fosters a sub-specialized skillset in areas related to market and digital logistics. As a clinical trialist and implementation scientist, Jocelyn has deep understanding of the nuances of continuous, episodic, synchronous, or asynchronous data collection techniques and EHR integration. Jocelyn has not only mastered strategies to meet product requirements for patient remote monitoring solutions set by IRBs but understands how to align product growth with provider and healthcare institutional mission and vision. In addition, Jocelyn’s work within ACO settings has afforded her keen awareness of and insights into innovative care models as well as healthcare reimbursement models to leverage shared savings programs and direct risk contracting in large academic and community systems. As the Director of the Community CAre Transitions (C-CAT) Initiative and the Director of Research Equity for the Division of General Internal Medicine, her clinical trial research is dedicated to innovative care models that leverage technology while promoting prevention for patient with serious illness. Clinically prepared in internal medicine and preventive medicine at Dartmouth-Hitchcock Medical Center, Dr. Carter is a valued member of the Massachusetts General Physicians Organization for Clinical Practice and Contracting Committee, the MassGeneral Brigham Executive Committee on Research in conjunction with the Mass General Brigham Institutional Review Board, the Contemporary Trials Editorial Board, the Society of General Internal Medicine Evidence-Based Medicine Sub-Committee (co-chair) and the ABIM’s American Board of Preventive Medicine Public Health Committee. | ||||||||||||||||||
| Colson | Yolonda | MD | MGH | Chief, Divison of Thoracic Surgery | Professor | Thoracic Surgery | Lung Cancer Localized Drug Delivery Healthcare Delivery | Yolonda Colson, MD is the Chief for the Division of Thoracic Surgery at Massachusetts General Hospital, Hermes C. Grillo Professor of Surgery at Harvard Medical School and the Vice President of the American Association for Thoracic Surgery. In addition to her cardiothoracic surgical training at Brigham and Women’s Hospital, her academic training includes a B.S. in Biomedical Engineering from Rensselaer Polytechnic Institute, an M.D. from Mayo Medical School, and a Ph.D. and general surgery residency at University of Pittsburgh. Career awards include: the inaugural Michael A. Bell Family Chair in Healthcare Innovation, the George H.A. Clowes, Jr. Research Career Development Award from the American College of Surgeons, the Edward M. Kennedy Award for Health Care Innovation, and serving as the current Exam Chair of the American Board of Thoracic Surgery. She is the current PI/co-PI on four NIH R01 Grants and recently has been elected to membership in the National Academy of Medicine. She has a specific clinical interest in improving the identification and treatment of lung cancer, increasing access to curative therapies, extending the chance of cure through novel technologies and broadening our understanding of the unique differences of lung cancer in women. Colson is co-inventor on three awarded patents and has received over twenty foundation grants and seven R29/R01 grants from the National Institutes of Health and National Cancer Institute. Her research focuses on the development of unique mechanisms of polymer and nanoparticle drug delivery aimed at preventing cancer recurrence, and the investigation of novel methods to identify hidden tumor that has spread to nearby lymph nodes. She has over 135 peer reviewed publications highlighting her previous work in transplantation and her most recent investigations in sentinel lymph nodes in lung cancer and polymer-mediated drug delivery. She has formally mentored well over 30 students, residents and junior faculty since becoming an attending thoracic surgeon | |||||||||||||||||
| Cudkowicz | Merit | MD | MGH | Chief, Neurology; Director, Sean M. Healy and AMG Center for ALS | Professor | Neurology | Neurological Disorders Clinical Trials | Merit Cudkowicz, MD is the Chief of the Massachusetts General Hospital Neurology Service, Director, Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, and the Julieanne Dorn Professor of Neurology at Harvard Medical School in Boston. Cudkowicz directs the Massachusetts General Hospital ALS Program and the Massachusetts General Hospital Neurological Clinical Research Institute. She is one of the founders and former co-directors of the Northeast ALS Consortium (NEALS), a group of over 100 clinical sites in the United States, Canada, Europe and the Middle East dedicated to performing collaborative academic led clinical trials and research studies in ALS. She is Principal Investigator of the Clinical Coordination Center for the National Institute of Neurological Disorders and Stroke’s Neurology Network of Excellence in Clinical Trials (NeuroNEXT). The NeuroNEXT network is an efficient phase II network to develop innovative and new treatments for people with neurological disorders. | As an clinical expert in amyotrophic lateral sclerosis, I am interested in approaches to accelerate therapy development in all neurodegenerative disorders. I launched the first platform trial in ALS and the first gene therapy for familial ALS. My passion is in early phase clinical trial design and conduct. As co-founder of the Northeast ALS Consortium and Principal Investigator of the NIH supporter NeuroNEXT phase 2 network for neurological disorders, my expertise is in forming collaborative initiatives to more rapidly bring findings from the laboratory to testing in people. | ||||||||||||||||
| Cunnane | Mary Beth | MD | MEE | Chief, Radiology and Assistant Professor of Radiology at Harvard Medical School | Professor | Mary Beth Cunnane attended Haverford College where she obtained a degree in Philosophy. She then completed medical school at the University of Pennsylvania. Following internship at Pennsylvania Hospital, she returned to Penn for Radiology Residency which she completed in 2002. She then moved to Boston for a Neuroradiology Fellowship at Massachusetts General Hospital. Following that fellowship she joined the staff in the department of Radiology at Mass Eye and Ear. In 2021 she was named Chief of the Department of Radiology at Mass Eye and Ear. Mary Beth is past President of the New England Roentgen Ray Society. She is a frequent invited speaker at the Radiologic Society of North America and at the American Society of Head and Neck Radiology. She serves as a Board Member at Odyssey Day School in Wakefield, MA and at the Commonwealth School in Boston, MA. | |||||||||||||||||||
| Curry | William | MD | MGH | Director, Neurosurgical Oncology | Professor | Neurosurgical Oncology | Neurosurgery Neuroscience Immuno-Oncology Cell Therapy Healthcare Delivery Leadership | William Curry, MD, is the Director of Neurosurgical Oncology at Mass General Hospital, co-Director of Mass General Neuroscience, and the Vice-Chair for Diversity, Equity, and Inclusion for the Department of Neurosurgery at MGH. Dr. Curry is Professor of Neurosurgery at Harvard Medical School. Curry is an international leader in the fields of brain tumor surgery, skull base surgery, brain tumor immunology and immunotherapy, and neurosurgery education. He also serves in multiple leadership roles at Mass General Hospital, including membership on the General Executive Committee, the Mass General Physicians’ Organization Executive Committee, and the Board of Trustees of the General Hospital Corporation (Mass General Hospital). He has recently been appointed to the Board of Directors of Mass General Brigham. | I am the Director of Neurosurgical Oncology at Mass General, and I am excited about cellular immunotherapy opportunities for patients with brain tumors. Furthermore, advances in translational neuroscience and neurotechnology will change the ability for patients to recovery from brain injury, including after surgery or adjuvant therapy for brain cancer. | ||||||||||||||||
| Eisen | Jane | MD | McLean | Clinical Director, Center of Excellence in Depression and Anxiety Disorders | Professor | Psychiatry | Neuroscience Psychiatry Anxiety Disorders Obsessive-Compulsive Disorder | Jane Eisen, MD is clinical director of the Center of Excellence in Depression and Anxiety Disorders at McLean Hospital, overseeing the integration of clinical work and research in the division. Her clinical responsibilities include her work in The Pavilion, where she evaluates and treats individuals with complex psychiatric disorders. Eisen’s clinical and research areas of interest are anxiety disorders and obsessive-compulsive disorder, and she also has a longstanding interest in education, as well as faculty development. She has been involved in the National Neuroscience Curriculum Initiative (NNCI) since 2013, and currently serves as chair of the NNCI’s faculty development task force. Eisen joined the faculty at McLean after serving as training director and vice chair of Academic Affairs in the Brown Department of Psychiatry and Human Behavior and more recently as chair of the Department of Psychiatry at Mt. Sinai St. Lukes and Mt. Sinai West in New York City. | |||||||||||||||||
| Ferrone | Cristina | MD | MGH | Director, MGH Liver Surgery Program | Gastrointestinal Surgery | Cristina Ferrone is a pancreatic and hepatobiliary surgeon at the Massachusetts General Hospital. She has been the Associate Program Director of the General Surgery Residency Program since 2006. She has mentored many female residents, medical, college and high school students. She is the director of the Liver Program and started the laparoscopic pancreatic and liver programs at the MGH. She did her undergraduate degree at the University of Pennsylvania and medical school at Washington University in St. Louis. She completed her general surgery residency in 2004 at the Massachusetts General Hospital and her surgical oncology fellowship in 2006 at Memorial Sloan Kettering Cancer Center. She has focused her clinical and basic science research on neoadjuvant therapy and pancreatic adenocarcinoma and cholangiocarcinoma. | |||||||||||||||||||
| Gainer | Lindsay | RN, MSN | McLean | Vice President of Operations Development | Lindsay Gainer, RN, MSN is the Vice President of Operations Development for Mass General Brigham Integrated Care. In her role, Lindsay plays a critical role in the overall start up, strategic development, and management of a new, innovative ambulatory strategy for Mass General Brigham. Lindsay directs the initiation and operations of all new ambulatory sites across the network, including development of operating processes, care model design, and management of staff. As MGB iCare embarks upon a strategic plan to realize a compelling new vision for the future of ambulatory care, Lindsay serves as a strategic partner to organizational leaders, providing site operational perspective and insight to guide decisions, as well as leading the operations of the sites once established. Lindsay has over 20 years of experience in healthcare and has been a nurse leader for most of her career. Most recently, she served as the Senior Executive Director of Innovation for North Shore Medical Center (NSMC) and North Shore Physicians Group (NSPG) in Salem, Massachusetts; the second largest community hospital in Massachusetts, and one of the largest, community-based, multispecialty physician groups in the state. Her responsibilities included leadership of the Kaizen Promotion Office, strategy deployment, clinical operations, quality and safety, population health management, staff development and training. Lindsay received her Bachelor of Science in Nursing and her Master of Science in Nursing and Health Care Systems from the University of North Carolina at Chapel Hill. Lindsay’s areas of expertise are in clinical operations, improvement science, change management, Lean, care model redesign, spread of innovation, strategy deployment, high reliability systems, and population health management. Her scholarly achievements include multiple publications and presentations and her research interests lie in health care policy and systems issues, with primary focuses in quality, patient safety, process improvement, and professional development. Lindsay was previously a Clinical Assistant Professor at UNC-Chapel Hill and Nurse Manager of the Hematopoietic Stem Cell Transplant Unit at Boston Children’s Hospital. Lindsay is active in multiple professional organizations and has served on the Board of Directors of the North Carolina Nurses Association and the Massachusetts Association of Registered Nurses. | ||||||||||||||||||||
| Garibyan | Lilit | MD, PhD | MGH | Physician-Scientist, Wellman Center for Photomedicine | Assistant Professor | Dermatology | Pain Technology Development Clinician-led Innovation Innovation Education | Lilit Garibyan MD, PhD is an Assistant Professor of Dermatology at Harvard Medical School and a Physician-Scientist at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH). Her research focuses on innovative biomedical translational discoveries aimed at identifying novel treatments for dermatologic diseases and beyond. She is an expert in injectable tissue cooling technology for the treatment of pain and removal of unwanted fat tissue. She is an inventor on many patents, some of which has led to the development of startup companies. She is also the co-founder and the Director of the “Magic Wand Initiative” and the Virtual Magic Wand programs, which are recognized nationally and internationally and aim to promote and empower clinician-led research and innovation by teaching the process of innovation. Garibyan has co-authored numerous peer-reviewed original publications. She has lectured at national and international levels and has developed a reputation as an expert and leader in dermatology and biomedical innovation. As a humanitarian, she has pioneered and established sustainable, medical laser clinics in Armenia for the effective treatment of scars and vascular anomalies. Garibyan recently founded and serves as president of a nonprofit organization called “Face of Angel” to continue the mission of this humanitarian work. Garibyan received her BS summa cum laude from University of California Los Angeles, her MD from Harvard Medical School and her PhD from Harvard University in Experimental Pathology/Immunology. | I am a physician-scientist at Wellman Center for Photomedicine and assistant Professor in Dermatology at Harvard Medical School. I co-invented, developed and pioneered the use of injectable ice-slurry device as a new way of cooling tissue for therapeutic use. I am leading the development of ice-slurry as a new method of fat removal from the tongue, for treatment of obstructive sleep apnea. My work also showed that a single injection of ice slurry around a peripheral nerve reduces physiologic pain sensation for up to 2 months. We are developing this to be a long-lasting opioid free treatment for peripheral nerve pain following surgery. I am the co-founder of a biotech company launched in 2019 to commercialize this new technology. I am passionate about problem-based innovation that has direct impact on patient care. I love helping other physician identify, deeply understand, and solve problems through innovation. I co-founded and direct a global initiative (www. MagicWandInitiative.org ) that is doing that. | ||||||||||||||||
| Golby | Alexandra | MD | BH | Director, Image-Guided Neurosurgery | Professor | Neurosurgery | Neurosurgery Neuroimaging Brain Mapping Image-guided Interventions | Alexandra Golby, MD, is a neurosurgeon and Director of Image-guided Neurosurgery at Brigham and Women’s Hospital in Boston and Professor of Neurosurgery and Radiology at Harvard Medical School. She holds the Haley distinguished Chair in the Neurosciences at BWH. She is also Principal Investigator of Golby Lab, a surgical brain mapping laboratory. She graduated from Yale University with a B.A. in Physics and Philosophy in 1989 and an M.D. from Stanford University School of Medicine in 1995. She was a resident in Neurosurgery at Stanford University and Chief Resident at BWH/Boston Children’s Hospital graduating in 2002. After residency she studied with Professor Benabid, inventor of deep brain stimulation, in Grenoble France under a CNS Dandy Fellowship. Golby has special clinical interests in brain surgery for patients with brain tumors and epilepsy, especially those lesions which are intimately associated with critical brain structures. She has developed numerous technologies to help guide presurgical planning and intraoperative decision making. Her research at the Golby Lab focuses on functional brain mapping with functional MRI and diffusion MRI-based white matter mapping. In addition, she works with intraoperative imaging including intraoperative ultrasound and intraoperative MRI. Projects related to measurement of brain shift and identification of tumor tissue intraoperatively are an additional important focus of her team’s work and collaborative efforts. Other interdisciplinary research focused on intraoperative guidance investigates the use of fluorescence and other optical techniques as well as mass spectrometry for tissue characterization. She also currently leads a clinical trial of focused ultrasound for blood brain barrier disruption in patients with glioblastoma. She works closely with scientists across many disciplines including computer science, applied mathematics, MR and ultrasound physics, and biomedical engineering. | I am a professor of Neurosurgery and of radiology at HMS working as a clinician scientist at Brigham and Women’s Hospital. My work centers on the use of advanced imaging and image guidance to inform pre-surgical planning and surgical decision-making for patients undergoing brain surgery. We also work with novel approaches such as laser interstitial thermal ablation and focused ultrasound for blood brain barrier opening. I am driven by the goal of helping patients dealing with very difficult and often life altering diagnoses and the surgeons and clinicians taking care of those patients. An area of innovation which I am particularly interested in is developing low cost solutions which implement complex technology so that more patients and the doctors caring for them can benefit from advances in imaging. | ||||||||||||||||
| Greenfield | Shelly | MD | McLean | Chief Academic Officer, Divison of Women's Mental Health | Professor | Psychiatry | Substance Use Disorders Mental Health Women’s Health Health Care Services Delivery for Addiction and Mental Health Disorders Addiction/Mental Health Behavioral and Pharmacotherapy Treatments Global Health Health Disparities Faculty Development Digital Health | Shelly F. Greenfield, MD, MPH is Professor of Psychiatry at Harvard Medical School and the Kristine M. Trustey Endowed Chair of Psychiatry at McLean Hospital where she also serves as the Chief Academic Officer. She is the Chief of the Division of Women’s Mental Health and the Director of Clinical and Health Services Research and Education in the Alcohol, Drug and Addiction Treatment Program at McLean Hospital. Greenfield is an addiction psychiatrist, clinician and researcher. Greenfield has served as Principal Investigator and Co-Investigator on federally funded research focusing on treatment for substance use disorders, gender differences in substance disorders, and health services for substance disorders. She received a National Institute on Drug Abuse (NIDA)-funded career award in substance use disorder patient oriented research (2005-2016). Funded by grants from NIH/NIDA, she developed and tested a new manual-based group therapy for women with substance use disorders, the Women’s Recovery Group (WRG). The WRG is an evidence-based treatment and the manual for dissemination was published in 2016, Treating Women with Substance Use Disorders: The Women’s Recovery Group Manual. She is immediate Past President of the American Academy of Addiction Psychiatry and current member and past chair of the American Psychiatric Association’s Council on Addiction Psychiatry. She is immediate past Editor-in-Chief of the Harvard Review of Psychiatry, a position in which she served for 16 years (2002-2018). Greenfield was a member of the Advisory Committee on Services for Women for the U.S. Substance Abuse and Mental Health Services Administration (2011-2017). She has been elected to the American College of Psychiatrists and the College on Problems of Drug Dependence, and is a Distinguished Fellow of the American Psychiatric Association. She received the R. Brinkley Smithers Distinguished Scientist Award from the American Society of Addiction Medicine and the A. Clifford Barger Award for Excellence in Mentoring from Harvard Medical School. | |||||||||||||||||
| Greka | Anna | MD, PhD | BH | Associate Physician, Renal Division | Associate Professor | Genes and Disease Rare Disease Metabollic Disease Age-related Disease | Anna Greka, MD, PhD, is an institute member of the Broad Institute of MIT and Harvard, where she leads a program focused on dissecting basic molecular and cellular mechanisms that may ultimately serve as the foundation for the development of targeted therapies. She is an associate professor at Harvard Medical School (HMS), and an associate physician in the Renal Division in the Department of Medicine at Brigham and Women’s Hospital. The mission of the Greka laboratory is to define fundamental aspects of membrane protein biology and dissect mechanisms of cellular homeostasis. The laboratory complements this cell biology-focused program with tools from molecular biology, genomics, proteomics, and chemical biology. Greka holds an A.B. in biology from Harvard College and an M.D. and Ph.D. in neurobiology from HMS. She received her medical and scientific training in the Harvard-MIT program in Health Sciences and Technology in the laboratory of David Clapham. | ||||||||||||||||||
| Haas-Kogan | Daphne | MD | BH | Chair, Department of Radiation Oncology | Professor | Radiation Oncology | Radiation Oncology Pediatric Oncology Novel Targeted Cancer Therapies | Daphne Haas-Kogan, MD, is chair of the Department of Radiation Oncology at Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Boston Children’s Hospital. She is a Professor of Radiation Oncology at Harvard Medical School. As chair of the Department of Radiation Oncology, her vision includes supporting each member of the department in fostering close collaborative ties with diagnostic radiologists, medical and pediatric oncologists, surgeons, pathologists, and basic science investigators to spearhead cutting edge science, translational investigations and clinical studies, all based on the depth and breadth of success that already permeates Dana- Farber/Brigham and Women’s Cancer Center (DFBWCC). Haas-Kogan’s laboratory research has focused on characterizing aberrant signaling pathways in gliomas and investigating agents that target these signaling cascades. She has been the Principal Investigator on many grants funded by NIH/NCI, philanthropic organizations, and industry collaborations. She has been selected as one of the top physicians in the United States by several publications including Best Doctors in America, San Francisco Magazine, and Consumers’ Research Council of America. She has also received several teaching awards including the Henry J. Kaiser Award for Excellence in Teaching from UCSF School of Medicine. Haas-Kogan continues to pursue laboratory research, design clinical trials, establish robust collaborations, and develop a thriving clinical practice in radiation oncology. In 2016, she was appointed to the Blue Ribbon Panel of scientific experts, cancer leaders, and patient advocates that will inform the scientific direction and goals at NCI as part of Vice President Joe Biden’s National Cancer Moonshot Initiative. She was also elected to the Association of American Physicians and the National Academy of Medicine, and awarded a Fellowship by the American Society of Radiation Oncology. Haas-Kogan received her undergraduate degree in biochemistry and molecular biology magna cum laude from Harvard University and her MD from the University of California, San Francisco. She completed her residency in Radiation Oncology and post-doctoral fellowship in molecular neuro-oncology at UCSF. She remained at UCSF as a tenure track faculty member with joint appointments in Radiation Oncology and Neurological Surgery, was Vice Chair for Research since 2003, and Educational Program Director since 2008. | |||||||||||||||||
| Joffe | Hadine | MD | BH | Vice Chair, Psychiatry Research; Executive Director, Mary Horrigan Connors Center for Women's Health and Gender Biology | Professor | Psychiatry | Menopause Psychiatry Breast Cancer Women's Health | Hadine Joffe, MD, is a psychiatrist and clinical reproductive neuroscience investigator who conducts clinical and translational research focused on women’s brain health, specifically on the interface between reproductive endocrinology, sleep, and mental health. | Novel pharmacotherapies for treatment of neuropsychological symptoms (hot flashes, insomnia, depression, fatigue) in health women during midlife and in those undergoing anti-estrogen therapies for breast cancer. Therapeutic strategies involving drugs, devices, and digital innovations for diseases that affect women and men that can be advanced through the inclusion of female-specific and sex/gender-differentiating knowledge. | ||||||||||||||||
| Johnson-Akeju | Oluwaseun | MD | MGH | Anesthetist-in-Chief | Associate Professor | Anesthesia | Anesthesia Sleep Pain Pharmacology Neurophysiology | Oluwaseun Johnson-Akeju, MD, is the anesthetist-in-chief at Massachusetts General and an Associate Professor of Anesthesia at Harvard Medical School. His clinical practice is primarily devoted to the care of patients with neurological diseases. His research interests are interdisciplinary and focus on using anesthesia as a probe to study mechanisms of fundamental neurobiological processes. Johnson-Akeju received a Bachelor of Science degree from the New Jersey Institute of Technology, a Doctor of Medicine degree from Rutgers–The New Jersey Medical School, and a Master of Medical Science degree from Harvard Medical School. He completed his internship and residency training in anesthesiology at Massachusetts General Hospital and post-doctoral research training at Harvard University. | |||||||||||||||||
| Jurkunas | Ula | MD | MEE | Associate Professor of Ophthalmology, Associate Scientist Co-Director Cornea Center of Excellence, Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School | Associate Professor | Ophthalmology | Dr. Ula Jurkunas is a clinician-scientist in the Cornea and Refractive Surgery Service at Mass. Eye and Ear and a Co-director of the Harvard Medical School (HMS) Ophthalmology Cornea Center of Excellence. She conducts basic science and clinical research on Fuchs endothelial corneal dystrophy and stem cell transplantation of the ocular surface. In addition, she teaches residents and fellows about corneal surgical procedures as well as diagnosis and clinical management of corneal and refractive conditions. Her main clinical areas of expertise are corneal endothelial dysfunction, femtosecond cataract surgery, refractive surgery, and lamellar keratoplasty, including DMEK and complex DSAEK. Dr. Jurkunas heads a fully-staffed and RO1-NIH funded laboratory, which studies the mechanisms involved in the corneal endothelial degeneration seen in Fuchs dystrophy. Her studies focus on the role of oxidative stress in cell-extracellular matrix interactions, estrogen metabolism, DNA damage and repair, and mitochondrial biogenesis in Fuchs dystrophy. Moreover, she has pioneered the development of cultivated epithelial (stem) cell transplantation for the treatment of limbal stem cell deficiency. The latter studies have led to the translational development of stem cell therapy in corneal disorders . She has received an UG1 NIH/NEI grant to perform a Phase I/II study using stem cells to treat unilateral limbal stem cell deficiency. The first-in-human study using cultivated autologous limbal epithelial cells (CALEC) transplantation is currently underway at Mass. Eye and Ear. Her work has led to numerous peer-reviewed publications, review articles, and both national and international presentations. Dr. Jurkunas has received numerous awards, including Research to Prevent Blindness Award, ARVO Alcon Early Clinician-Scientist Research Award, Alcon Research Institute Award, AAO Achievement Award, and, most recently, ARVO Foundation/Pfizer Ophthalmics Carl Camras Translational Research Award. | ||||||||||||||||||
| Kaiser | Ursula | MD | BH | Chief, Division of Endocrinology, Diabetes, and Hypertension | Dr. Ursula Kaiser received her medical degree and completed her clinical residency in Internal Medicine and clinical fellowship in Endocrinology at University of Toronto School of Medicine, and she completed a post-doctoral research fellowship at Brigham and Women’s Hospital and Harvard Medical School before joining their faculty. Dr. Kaiser has an active research program focused on the genetic and molecular mechanisms underlying the neuroendocrine regulation of puberty and reproduction. Her research has received continuous NIH support for more than thirty years and she is the author of more than 140 peer-reviewed publications. She serves as Program Director of the NIH-funded Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) K12 program to train junior faculty in women’s health research, and the Principal Investigator of an NIH T32 training grant to train physicians and scientists in academic endocrinology. Dr. Kaiser is also an active clinician, focusing on neuroendocrinology and reproductive endocrinology. She has successfully mentored over 30 students, fellows and other trainees, many of whom have gone on to independent academic faculty positions. She is the recipient of the A. Clifford Barger Excellence in Mentoring Award at Harvard Medical School. Dr. Kaiser is a member of the American Society of Clinical Investigation and the Association of American Physicians, is a Fellow of the American College of Physicians, and a member of the Board of Scientific Counselors for the Eunice Kennedy Shriver National Institute of Child Health and Human Development. She is the recipient of the Ernst Oppenheimer Award and the Sidney H. Ingbar Award of the Endocrine Society. Dr. Ursula Kaiser received her medical degree and completed her clinical residency in Internal Medicine and clinical fellowship in Endocrinology at University of Toronto School of Medicine, and she completed a post-doctoral research fellowship at Brigham and Women’s Hospital and Harvard Medical School before joining their faculty. Dr. Kaiser has an active research program focused on the genetic and molecular mechanisms underlying the neuroendocrine regulation of puberty and reproduction. Her research has received continuous NIH support for more than thirty years and she is the author of more than 140 peer-reviewed publications. She serves as Program Director of the NIH-funded Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) K12 program to train junior faculty in women’s health research, and the Principal Investigator of an NIH T32 training grant to train physicians and scientists in academic endocrinology. Dr. Kaiser is also an active clinician, focusing on neuroendocrinology and reproductive endocrinology. She has successfully mentored over 30 students, fellows and other trainees, many of whom have gone on to independent academic faculty positions. She is the recipient of the A. Clifford Barger Excellence in Mentoring Award at Harvard Medical School. Dr. Kaiser is a member of the American Society of Clinical Investigation and the Association of American Physicians, is a Fellow of the American College of Physicians, and a member of the Board of Scientific Counselors for the Eunice Kennedy Shriver National Institute of Child Health and Human Development. She is the recipient of the Ernst Oppenheimer Award and the Sidney H. Ingbar Award of the Endocrine Society. | ||||||||||||||||||||
| Kelly | Hillary | MD | MGH | Director, Head and Neck Imaging | Assistant Professor | Radiology | Radiology Neuroimaging Head and Neck Cancer | Hillary Kelly, MD, is a Staff Radiologist at Massachusetts Eye and Ear, the Director of Head and Neck Imaging, Division of Neuroradiology at Massachusetts General Hospital and an Assistant Program Director for the Diagnostic Radiology Residency at MGH. She specializes in Neuroradiology, with clinical interests including head and neck cancer, temporal bone disorders, thyroid and parathyroid imaging and pathology. Kelly attended Harvard Medical School and completed her training at Massachusetts General Hospital. She is also an Assistant Professor of Radiology at Harvard Medical School. | I am a Neuroradiologist specializing in Head and Neck Imaging, with clinical appointments at both Massachusetts General Hospital and Massachusetts Eye and Ear. I have particular clinical and research interests in innovation in CT and MR imaging for evaluation of head and neck cancer and thyroid and parathyroid disease, and have lectured nationally and internationally on these topics. I am interested in and passionate about innovation not only in diagnostic imaging, but also in image-guided therapeutics in the head and neck. | ||||||||||||||||
| Lee | Jeannie | MD, PhD | MGH | Professor, Genetics | Professor | Genetics Pathology | Molecular Biology X-linked Disorders Rett Syndrome Fragile X Syndrome Epigenetics RNA Therapeutics X Reactivation Noncoding RNA | Jeannie T. Lee, MD, PhD, is a Professor of Genetics (and Pathology) at Harvard Medical School, the Blavatnik Institute, and the Massachusetts General Hospital. Lee specializes in the study of epigenetic regulation by long noncoding RNAs and uses X-chromosome inactivation as a model system. Growing knowledge of X-inactivation mechanisms and RNA biology is currently being translated to treat various human diseases, including Rett, Fragile X, and CDKL5 Syndromes. As a champion of translational science, Lee played a major role in the founding of Translate Bio and Fulcrum Therapeutics. She is also a Scientific Advisor to Skyhawk Therapeutics. Lee is a Member of the National Academy of Sciences and has received several other honors, including a 2018 Harrington Rare Disease Scholar Award from the Harrington Discovery Institute, the 2016 Lurie Prize from the Foundation for the National Institutes of Health, and the 2016 Centennial Prize from the Genetics Society of America. Lee was also named a Distinguished Graduate of the University of Pennsylvania School of Medicine in 2013 and was an Investigator of the Howard Hughes Medical Institute (2000-2018). From 2013-2018, she co-launched the Epigenetics Initiative at Harvard Medical School and served as its Co-Director. She also served on the Board of Directors of the Genetics Society of America and later served as its President, establishing a strategic plan and development strategy for the society in 2018. Lee received her AB in Biochemistry and Molecular Biology from Harvard University and her MD and PhD from the University of Pennsylvania School of Medicine. She then carried out postdoctoral work at the Whitehead Institute & MIT and became Chief Resident of Clinical Pathology at the Massachusetts General Hospital prior to joining the Faculty at Harvard Medical School. | |||||||||||||||||
| Lehman | Constance | MD, PhD | MGH | Professor, Radiology | Professor | Radiology | Artificial Intelligence Radiology Health Care Delivery Equity and Inclusion Clinical Trials Breast Cancer Oncology | Constance “Connie” Lehman, MD, PhD is Professor of Radiology at Harvard Medical School and an internationally recognized clinical leader in breast cancer imaging. After graduating Phi Beta Kappa from Duke University, Dr. Lehman earned her MD and PhD from Yale University and holds an honorary medical degree from Harvard Medical School. She has co-authored over 275 peer-reviewed scientific publications addressing the performance of imaging tests in diverse settings, including guidelines for the American Cancer Society, the American College of Radiology, and the National Comprehensive Cancer Network. She has formally mentored well over 50 students, residents, fellows and faculty, many of whom are leaders at their current institutions. In 2020 she co-founded Clairity, Inc., a company dedicated to change the current paradigm for cancer screening, through the power of AI applied to imaging of the human body. Collectively, her philosophy embodies the notion that we improve the health of our community by delivering high value, equitable, patient-centered care in a setting of active innovation and change. | I am grateful to mentors throughout my career who modeled creative and passionate approaches to improve the health of others. As a doctoral student in psychology at Yale, I was inspired by the enthusiasm and dedication of faculty to integrate diverse opinions, approach challenges with open and curious minds, and effect real change. In Seattle at the University of Washington and Fred Hutchinson Cancer Research Center, I was supported to engage with multidisciplinary teams to provide higher value care to our local and global communities. I was delighted in 2015 to join the faculty of the Harvard School of Medicine and MGH Radiology, and continue to be inspired daily by my colleagues and community members locally and globally to accelerate progress in our shared mission to expand access for all of our patients to innovative, high quality, patient-centered, affordable care. My core values have focused on attracting and retaining the very best people, identifying their goals and passions aligned with the institutional mission, and then providing them the infrastructure and tools to support their success. I have developed strategic pathways to streamline workflow, across clinical, educational, research and community service domains, to support fiscally sound structures for the stability and growth of systems required to sustain our shared mission. | ||||||||||||||||
| Logan | Merranda | MD, MPH | MGB | Associate Chief Academic Officer | Faculty | Nephrology | Healthcare Equity, Quality and Safety Healthcare Administration Research Management Leadership Internal Medicine Nephrology End Stage Renal Disease | Merranda Logan, MD, MPH, is the Associate Chief Academic Officer at Mass General Brigham. She leads system-wide strategies to promote scientific discovery, efficiency in research administration, cost reduction, and innovation in graduate medical education. She is also a practicing nephrologist at Massachusetts General Hospital and faculty at Harvard Medical School. Prior to her current role, she served as the Associate Chief Quality Officer at Massachusetts General Hospital, Site-Director for Harvard Medical School Fellowship in Quality & Safety, and Director for Fellow Wellbeing in the Department of Medicine. Dr. Logan’s leadership and research interests include healthcare quality and safety, organizational efficiency and workplace culture. Her clinical expertise includes Internal Medicine, Nephrology and End Stage Renal Disease. Dr. Logan was born in Philadelphia, Pennsylvania and comes from a long lineage of educators. Dr. Logan graduated from Barnard College of Columbia University with a bachelor’s degree in Neuroscience & Behavior and received her Medical Degree from Howard University College of Medicine, a Historically Black University (HBCU). She received a Master’s Degree in Public Health from the Harvard School of Public Health. Dr. Logan trained in Internal Medicine and was a Chief Resident at Temple University Hospital in Philadelphia and completed a fellowship in Nephrology at Mass General Brigham. Dr. Logan completed additional fellowships in Patient Safety & Quality Improvement at Harvard Medical School and was a physician fellow at The Joint Commission. | |||||||||||||||||
| Madras | Bertha | PhD | McLean | Director, Laboratory of Addiction Neurobiology | Professor | Neurobiology | Neuroimaging Neurobiology and Addiction Public Policy | Bertha K. Madras, PhD, is a professor of psychobiology at Harvard Medical School, based at McLean Hospital and cross appointed at the Massachusetts General Hospital. Her research focuses on neurobiology, imaging, and medications development (19 U.S. and 27 international patents) for neuropsychiatric disorders. In public policy, she was deputy director for demand reduction in the White House Office of National Drug Control Policy, a presidential appointment confirmed unanimously by the U.S. Senate. Madras recently served as a panelist at the Vatican Pontifical Academy of Sciences and in 2017, was appointed as one of six members of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. In service to the public, she developed a museum exhibit and a CD (licensed by Disney) with the Museum of Science, Boston. She is recipient of an NIH MERIT award, a NIDA Public Service Award, and others. | |||||||||||||||||
| Maus | Marcela | MD, PhD | MGH | Director, Cellular Immunotherapy Cancer Center | Associate Professor | Immuno-Oncology | Immuno-Oncology Cell Therapy CAR-T | Marcela Maus, MD, PhD, is the Director of Cellular Immunotherapy at the Massachusetts General Hospital Cancer Center and an Attending Physician in the Bone Marrow Transplant and Cell Therapy division of Hematology/Oncology at the Massachusetts General Hospital. Maus is an Assistant Professor at Harvard Medical School, an Associate Member of the Broad Institute of Harvard and MIT, and an Associate Member of the Ragon Institute of MGH, MIT, and Harvard. Maus is a translational physician-scientist in the field of immunology, particularly as it relates to cancer. Her research program spans basic mechanisms of human immunology to design and test novel immune-based therapeutic interventions in vitro, in mouse models, and in patients. Her group has initiated novel clinical trials of cell therapies in lymphoma, myeloma, glioblastoma, and has ongoing projects to enhance CAR T cells for multiple solid tumors. Maus received her bachelor’s degree from the Massachusetts Institute of Technology, and her MD and PhD from the University of Pennsylvania. She trained in internal medicine at University of Pennsylvania and in hematology and medical oncology at Memorial Sloan Kettering, and is board-certified in these three disciplines. Her laboratory research training was focused on gene and cell therapies, and occurred in the laboratories of Dr. Katherine High, Dr. Michel Sadelain, and Dr. Carl June. | I am an oncologist and immunologist, and the Director of the Cellular Immunotherapy program in the Cancer Center at Mass General. We develop novel forms of gene-modified immune cells, particularly T cells, to direct them to cancer. My 3 passions are immunology, gene therapy, and developing transformative cancer therapies. What excites me the most is to bring new ideas and immunotherapies into the clinic in a phase I trial, and to complete the bench to bedside and back to bench circle. In the field of gene and cell therapy, the entire circle can be completed in the hospital, but of course, to go beyond Phase I and change the standard of care, industry involvement and scale are critical. I do serve on several Scientific Advisory Boards and Data Safety Monitoring Boards for companies developing cell and gene therapies, for cancer indications as well as other diseases like autoimmunity. I also serve on one board of directors, with a biotech company working on antibody-based immunotherapy for cancer. One of my near-term goals is to found a new company, and eventually become a “serial entrepreneur.” What I can contribute to a board is domain expertise in clinical, scientific, and regulatory processes for development of immunotherapies. Some of the things I want to learn are what makes a successful company, decisionmaking processes at higher levels, organizational structures, and developing complex therapies beyond Phase I and the academic setting. My main questions are about how to choose which opportunities to take and which to decline, and how to approach and manage potential conflicts of interest in a transparent and unambiguous way. | ||||||||||||||||
| McDonnell | Marie | MD | BH | Chief, Diabetes Section and Director, Diabetes Program | Lecturer | Diabetes | Diabetes Blood Glucose Management Islet Cell Replacement Therapy Medical Education and Training Leadership | Marie McDonnell, MD, is Chief of the Diabetes Section in the Division of Endocrinology, Diabetes and Hypertension at Brigham and Women’s Hospital and Harvard Medical School in Boston. In her current role as Director of the Diabetes Program at Brigham Health, McDonnell provides clinical, academic, and administrative leadership of the hospital-wide diabetes program. A graduate of Boston University School of Medicine, the New York Presbyterian Hospital- Columbia residency program, and Endocrinology fellowship at Boston Medical Center, McDonnell’s clinical research focus is health outcomes of scalable specialty-level diabetes care delivery services in the acute and ambulatory settings. In 2017, she was a founding faculty member of the Boston Autologous Islet Replacement Therapy (BAIRT) consortium that includes Brigham and Women’s Hospital, Joslin Diabetes Center, Harvard University, Semma Therapeutics and Dana Farber Cancer Institute. BAIRT aims to develop methodology to provide autologous stem cell derived beta cells to people with diabetes and to demonstrate this approach as an effective treatment strategy. McDonnell teaches medical students at Harvard Medical School and is key faculty for both the Medicine and Endocrinology training programs at Brigham and Women’s Hospital. She delivers multiple local, regional and international lectures and webinars per year in the field of Diabetes Care. A highly engaged clinician, she has served on several national committees and was appointed Chair of the Endocrine Society Guidelines committee for 2021. She has co-authored the Society of Thoracic Surgeons practice guideline on blood glucose management during adult cardiac surgery, and multiple Endocrine Society guidelines, including the Pharmacologic Management of Obesity, and Management of Diabetes in Older Adults and the Management of Hyperglycemia in the Hospital Setting. | |||||||||||||||||
| Miller | Joan | MD | MEE | Chief of Ophthalmology | Professor | Ophthalmology | Innovation Clinical Translation Retinal Disease Age-related Macular Degeneration Compliance | Joan Miller, MD, is the David Glendenning Cogan Professor and Chair of the Department of Ophthalmology at Harvard Medical School (HMS), Chief of Ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital, and Ophthalmologist-in-Chief at Brigham and Women’s Hospital. A graduate of Massachusetts Institute of Technology (MIT), she earned her MD from HMS and completed her ophthalmology residency and vitreoretinal fellowship at Mass Eye and Ear. Her clinical research interests focus on retinal disorders, including age-related macular degeneration (AMD). Miller and her colleagues at Mass Eye and Ear/HMS pioneered the development of verteporfin photodynamic therapy (Visudyne®), the first pharmacologic therapy for AMD. The group also identified the key role of vascular endothelial growth factor (VEGF) in ocular neovascularization, leading to the development of anti-VEGF therapies now administered to millions of people with sight-threatening retinal diseases annually around the world. Her current studies focus on the pathogenesis of AMD, including genomics, metabolomics, imaging, and functional measures; strategies for early intervention in AMD; and neuroprotective therapies for retinal diseases. An internationally recognized expert in the field of retina, Miller has published over 280 original articles and more than 95 book chapters, reviews, and editorials. A member of the National Academy of Medicine, she was the first female physician to achieve the rank of Professor of Ophthalmology at Harvard Medical School, and the first woman to chair the Department of Ophthalmology. Miller is also the first woman appointed as Chief of Ophthalmology at both Mass Eye and Ear and Massachusetts General Hospital. | am currently Chief of Ophthalmology at Mass Eye and Ear and Mass General Hospital and Ophthalmologist-in-Chief at Brigham and Women’s Hospital, as well as Chair of the Harvard Ophthalmology department. In my Chief role I am responsible for the clinical, research, and education programs of Mass Eye and Ear, with significant hospital administration including financial oversight, recruiting, and compliance. As a member of the Mass Eye and Ear Board of Directors, I help develop and lead the institutional strategy. I am a retina specialist by training, and was a key team member in the development of the first two therapies for agerelated macular degeneration (AMD), the most common blinding eye disease in people over age 50. My work included animal studies, design of clinical trials, the regulatory process, and introduction of new therapies to clinicians. I am interested in serving on corporate boards because I want to participate in drug and device development from the business perspective. I believe my administrative and clinical knowledge, as well as my leadership experience, will allow me to contribute in a meaningful way. My current research includes the study of genomics, metabolomics and imaging biomarkers in retinal disease, as well as neuroprotection strategies in retinal disease. In addition, in overseeing the ophthalmology research portfolio I have gained broad exposure to gene-based therapies. I have served on a number of Scientific Advisory Boards, and served as an Independent Director on the Alcon Board of Directors. In addition to the Mass Eye and Ear Board, my volunteer board service includes foundation and advocacy boards. | ||||||||||||||||
| Nour | Nawal | MD | BH | Chair, Department of Obstetrics and Gynecology | Professor | Obstetrics and Gynecology | Global Women’s Health Obstetric Care Maternal Mortality Healthcare Equity, Quality and Safety | Nawal Nour, MD, is the Chair of the Department of Obstetrics and Gynecology at Brigham and Women’s Hospital. She holds the Kate Macy Ladd Professorship at Harvard Medical School. Prior to assuming the role of Chair of the Department of Obstetrics and Gynecology, Nour served as the Chief Diversity and Inclusion Officer for Faculty, Trainees and Students, since 2018. She has also served as the director of Ambulatory Obstetrics Practice for two decades and assumed leadership of the Ambulatory Gynecology Division last year. In addition, she is the Founding Director of the African Women’s Health Center and the Division Director of both Ambulatory Obstetrics and Gynecology. Recently named one of Forbes 40 Women to Watch Over 40, Nour established the world-renowned African Women’s Health Center which provides appropriate holistic health and outreach programs to the African community in Boston. As the founder and current director, Nour was honored as a 2003 MacArthur Foundation Fellow for creating the country’s only center of its kind that focuses on both physical and emotional needs of women who have had or undergone female genital cutting. Nour has also published several articles related to women’s health including, HIV and Pregnancy in resource-poor settings. Nour was born in the Sudan and raised in Egypt and England. She came to the United States to attend Brown University. She received her medical degree from Harvard Medical School, completed an Ob-Gyn residency in Obstetrics and Gynecology at the Brigham and Women’s Hospital and an MPH at Harvard School of Public Health. She has received numerous awards for her community work and outreach including honorary doctorate degrees from Bowdoin College and Williams College. Nour presently serves on the Brigham Health Board of Trustees. | |||||||||||||||||
| Eke | Onyinyechi | MD | MGH | Director, Global Ultrasound Department of Emergency Medicine and Instructor, Emergency Medicine Harvard Medical School | Instructor | Emergency Medicine | Dr. Onyinyechi Eke completed her undergraduate education at the University of Maryland, College Park and received her medical degree from Johns Hopkins School of Medicine, Baltimore. After residency training in emergency medicine at Cook County Hospital in Chicago, she completed a fellowship in emergency ultrasound at Massachusetts General Hospital, Boston. Dr Eke currently serves as faculty and director of global ultrasound in the Department of Emergency Medicine at Massachusetts General Hospital. Her research interests include the development of point-of-care ultrasound education and training in resource-limited settings, particularly in Sub-Saharan Africa and the efficient utilization of point-of-care ultrasound to facilitate patient care in the emergency department. | My long-term career goal is to become an international leader with expertise in establishing the evidence base for implementing and utilizing innovative strategies for point-of-care ultrasound (POCUS) training to improve patient outcomes and emergency care. My motivation stems from my own experience growing up in Nigeria, where I witnessed how the high cost of diagnostic imaging, in addition to a crumbling health infrastructure, delayed or precluded clinical care leading to adverse patient outcomes. During my emergency medicine residency, I trained in a tertiary-care county hospital where the large patient volumes and insufficient resources led to emergency department crowding, long wait times and variable clinical outcomes. It was in residency, that I saw the impact of POCUS on patient care; by making expeditious diagnoses, guiding clinical management and facilitating procedures at the bedside. As a 4th year resident, I participated in a rotation at Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. This is the largest referral hospital in the region where patients presented in hopes of seeking specialist care. Equipped with the clinical experience and POCUS training from residency, I taught residents POCUS utilizing a portable ultrasound device to diagnose and intervene in critically ill patients. Within the context of limited clinical and financial resources, and high cost of diagnostic imaging, I began to fully appreciate how POCUS could change clinical care in resource-limited environments outside of the United States. Following residency training, I spent a year as a clinical ultrasound fellow in the emergency department at Massachusetts General Hospital (MGH). During that time, I gained more in-depth training on POCUS research, in addition to supervising residents and other clinical providers as an attending physician. I also spent 2 weeks teaching POCUS and clinical skills to emergency medicine residents in New Delhi and Kolkata, India. All these clinical sites in Ghana, India and even in Boston, face critical patient overcrowding and heavy demand on resources, which has potential to compromise the delivery of quality patient care. As a supervising clinician, I was recently awarded the Clinician-Teacher Development Award from the MGH Center for Diversity and Inclusion to evaluate the implementation of tele-ultrasound, remote expert support for ultrasound use and interpretation, in the MGH emergency department. This development award will prepare me to rigorously evaluate innovative strategies for improving POCUS training at MGH and globally. I have witnessed the challenges of providing quality care that improves patient outcomes. I recognize the importance of supporting clinical innovation with analysis of efficacy and implementation, and how this will maximize the scale of the impact I desire to have through my research and practice. | |||||||||||||||||
| Paganoni | Sabrina | MD, PhD | MGH and SRH | Co-Director, Neurological Clinical Research Institute | Assistant Professor | Physical Medicine and Rehabilitation | Clinical Trials for Neurological Disorders, ALS | Sabrina Paganoni, MD, PhD, is the Co-Director of the Neurological Research Institute at the Massachusetts General Hospital and Assistant Professor at Harvard Medical School. Her research focuses on clinical trials and therapy development for ALS. She has served as PI of several ALS clinical trials and has been using novel trial designs, novel endpoints and digital technology tools to innovate the way investigational products are tested in ALS. She is the co-PI of the HEALEY ALS Platform Trial, the first platform trial for ALS in the world. She recently reported the positive results of the CENTAUR trial and is the co-Chair of the upcoming global PHOENIX trial. Her research has been funded by the NIH, non-profits, and industry; she published more than 100 peer-reviewed manuscripts and received several awards for her work including the 2021 Top 10 Clinical Research Achievement Award for the CENTAUR trial. | |||||||||||||||||
| Parangi | Sareh | MD | NWH | FACS-Professor of Surgery, Harvard Medical, Massachusetts General Hospital School, Chair of Surgery at Newton Wellesley Hospital | Professor | Targeted therapeutics, endocrine malignancies, thyroid cancer, surgery, animal models of cancer, diversity, equity and inclusion | Dr. Parangi is a Professor of Surgery at Harvard Medical School in Boston and a busy endocrine surgeon at Massachusetts General Hospital (MGH). She currently serves as Chair of Surgery at Newton Wellesley Hospital. She has interest and expertise in thyroid and parathyroid tumors. She focuses her clinical efforts on endocrine surgery and applies her basic science knowledge and expertise to tumor progression in thyroid cancer. She has repeatedly been one of the Boston surgeons named in Best of Boston in Boston Magazine and her excellence in both research and her clinical expertise have earned her a national reputation. Dr. Parangi graduated from Barnard College and earned her medical degree from Columbia University. She completed her residency at UCSF during which time she completed a Fellowship in Molecular Medicine. She is one of a handful of thyroid surgeons with expertise in molecular biology and has over 100 publications, many on thyroid cancer therapeutics in premier journal. She serves as the Director of Diversity and Inclusion in the MGH Department of Surgery. She is a Past President of The Association of Women Surgeons (AWS) and has in the past served as Treasurer of the most prestigious organization of endocrine surgeons in the US, The American Association of Endocrine Surgeons (AAES). She is also Secretary of the International Thyroid Oncology Group and a member of both the American Thyroid Association and American Association of Clinical Endocrinologists. She has won numerous awards nationally and at Harvard Medical School for her NIH funded research. Her active research focuses on understanding why some patients with thyroid cancer do worse than others and how to help them. This important research effort focuses on clarifying the molecular mechanism of thyroid cancer invasion and understanding the process of disease progression in patients with thyroid cancer. Her current projects focus on understanding the role of the immune system in the tumor microenvironment and how immunotherapy can be utilized to treat aggressive thyroid cancers such as anaplastic thyroid cancer. She has worked successfully with industry partners to bring novel drugs for thyroid cancer to clinical trials. She is active in many organizations that promote gender equity and diversity in surgery and medicine because she feels there is still a large need in promoting women to leadership positions in academia and surgical organizations. She believes that although promotion of women in surgical subspecialties has been slow which is obvious to her given her personal story on becoming the 2nd ever female Professor of Surgery at MGH, now is the time to institute bigger systematic changes that will ensure the best and the brightest get attracted to and succeed in surgery. | ||||||||||||||||||
| Peabody | Laura | MGB | Chief Legal Officer | General Counsel | Health Law Non-profit Corporate Governance Health Insurance | Laura is the Chief Legal Officer and General Counsel for Mass General Brigham (MGB), reporting to the President and CEO. Mass General Brigham (formerly known as Partners HealthCare) is a health system based in Boston Massachusetts founded in 1994 by Brigham and Women’s Hospital (BWH) and Massachusetts General Hospital (MGH), two of the nation’s leading academic medical centers. Laura’s responsibilities include providing legal and strategic counsel throughout Mass General Brigham, including to its Board of Directors. Laura manages a team of lawyers, paralegals and support staff with expertise in all areas of health care law. In addition, she oversees the Office for Interaction with Industry, a group that implements and oversees all policies relating to interactions with industry and outside activities. Laura is also responsible for Government Affairs (GA) at Mass General Brigham. The GA team manages government relations at the local, state, and federal level. This work includes partnering with internal and external lobbyists and trade associations to impact laws, regulations and public policy affecting MGB. Prior to joining MGB in 2017, Laura was Senior Vice President, Chief Legal Officer of Northwell, Inc., a major not-for-profit integrated health care delivery system serving the greater New York area. Before representing health systems, Laura spent many years representing healthcare payors. She was an attorney at Harvard Community Health Plan, Deputy General Counsel at Blue Cross Blue Shield of Massachusetts and General Counsel at Harvard Pilgrim Health Care (HPHC). Laura was the Chair of the Harvard Pilgrim Health Care Foundation board. Laura has also served on the boards of UNICEF, the Boston Bar Association, the Massachusetts Women’s Bar Foundation and the Elliot School in Jamaica Plain. She was recently elected to the Board of Trustees at McLean Hospital. Laura lives in Somerville, MA with her husband, Bob Peabody, and has two adult children and a daughter-in-law who live close by. | |||||||||||||||||||
| Pinder-Amaker | Stephanie | PhD | McLean | Program Director, College Mental Health Program and Chief Diversity, Equity, and Inclusion Officer | Assistant Professor | Psychology | College Mental Health Healthcare Equity, Quality and Safety Culturally Responsive Healthcare | Stephanie Pinder-Amaker, PhD, is an Assistant Professor at Harvard Medical School and the founding director of McLean Hospital’s College Mental Health Program (CMHP), a unique initiative serving students from over 200 institutions of higher education (IHEs), providing student-focused treatment; consultation services to schools; and related research. Since its inception in 2008, the CMHP has been collaborating with IHEs, secondary schools and non-profit organizations on how to infuse systems with evidence-based, culturally-responsive interventions that promote mental health, student well-being and academic achievement. Pinder-Amaker has consulted to institutions of higher education on developing multiculturally-responsive strategies for addressing the mental health needs of BIPOC and underrepresented students. Her commitment to the practice of Cultural Humility (Tervalon & Murray-Garica, 1998) is synonymous with mental health care. She co-founded Twin Star Intersectional Diversity Trainers and authored the forthcoming Beacon Press book, Did That Just Happen?! Beyond Diversity-Creating Sustainably Inclusive Organizations. Pinder-Amaker is a member of the WHO World Mental Health International College Student Initiative and serves on the boards of and/or as a senior advisor to several national organizations committed to racial justice and health equity including the Steve Fund, Active Minds, Boston Celtics United for Social Justice, and The Steppingstone Foundation. | I have served as McLean Hospital’s founding director of the College Mental Health Program (CMHP) since 2008 and became McLean’s first Chief Diversity, Equity & Inclusion Officer in 2020. The CMHP is a unique and innovative, data-driven initiative through which we provide clinical services to students and families, consult to institutions of higher education (IHEs), and conduct research for promoting college student mental health and wellness. Annually, students participate in McLean programs from over 200 IHEs--a demographic unique to our hospital. When consulting to IHEs we design workshops, trainings, and psychoeducational interventions on a broad range of topics. Since 2015, however, the top consultation request we have received from colleges, secondary schools and non-profits is this, “Can you help us to address the needs of our increasingly diverse student body?” For the CMHP, we have proactively focused on the needs of diverse, underrepresented and potentially marginalized students. So, we love answering this question and we are passionate about providing tools and resources that help schools answer this question more effectively. Just before the pandemic, we designed a new model, the Wellness Initiative for Student Equity (WISE), for helping schools to address the mental health needs of all students more effectively. The model is scalable such that, when launched, we will be able to reach many more schools and students than we have been able to work with previously. Given the longstanding mental health disparities which have been magnified in the past year, the need to develop WISE campuses will be even greater than ever. | ||||||||||||||||
| Price | Julie | PhD | MGH | Professor of Radiology, Harvard Medical School and Director of PET Pharmacokinetic Modeling at the. Athinoula A. Martinos Center for Biomedical Imaging | Professor | Radiology | Positron Emission Tomography, Neuroimaging, Alzheimer's Disease, Kinetic Modeling | Julie Price, PhD is a medical physicist with research expertise in quantitative Positron Emission Tomography (PET) methods for in vivo imaging of protein targets in healthy brain, aging, neuropsychiatric disorders, and neurodegeneration. This includes PET pharmacokinetic modeling studies for novel PET radiopharmaceutical development and evaluation applied in preclinical and human imaging studies. Dr. Price’s PI-level research primarily focuses on PET imaging of amyloid-beta (Aβ) and tau protein deposition in Alzheimer's disease. Prior research performed at the University of Pittsburgh, helped to establish [11C]-Pittsburgh Compound-B (PiB) for in vivo PET imaging of Aβ plaques in human brain. | |||||||||||||||||
| Salim | Ali | MD | BH | Chief, Division of Trauma, Burns, Surgical Critical Care and Emergency General Surgery | Professor | Trauma, Burns and Critical Care | Emergency General Surgery Trauma Surgery Surgical Critical Care | Ali Salim, MD, FACS, is a Professor of Surgery at Harvard Medical School and the Chief of the Division of Trauma, Burns, Surgical Critical Care and Emergency General Surgery at the Brigham and Woman’s Hospital in Boston, MA. He leads a team of trauma specialist in providing expert, multidisciplinary care for thousands of trauma and burn patients each year. Additionally, he is the Co-Medical Director of the Gillian Reny Stepping Strong Center for Trauma Innovation at Brigham and Women’s Hospital. Salim is both a Traumatologist and a Surgical Intensivist. He is a clinically active trauma, general, and critical care surgeon and devotes his time with equal intensity to research, surgical education and clinical service. His clinical interests focus on the care of the acutely ill trauma, emergency surgery and intensive care unit patient. Salim’s clinical research is focused on the care and outcomes of trauma patients, traumatic brain injury, improving the physiology of organ donors and improving the rate of organ donation. He has authored or co-authored over 350 peer-reviewed publications. Most recently his research has focused on racial disparities in organ donation, and on identifying and quantifying the long-term physical, emotional, and psychosocial effects following moderate to severe traumatic injury. | am the chief of Trauma, Burns, and surgical intensive care at the Brigham. For those non -physicians – my patient population is mostly the result of some sort of unexpected traumatic events, - car accidents, falls, assaults and interpersonal violence. In terms of an area of innovation that is exciting to me: One of the things the trauma community has not done well is understanding the long term effects and outcomes following injury. Trauma centers have not been equipped to really follow what happens to their patients once they are discharged. We have put in place a process to follow patients for up to a year after injury – but this process involves calling patients and asking a number of validated questions that can be time consuming and resource intensive. We recently starting looking at using smartphone based digital phenotyping to passively collect some of this data. Utilizing a smart phone app that is designed to collect data from smartphone sensors and usage logs. For example GPS data that can assess community integration: accelerometer activity to assess physical activity, anonymized phone call and text message logs to assess for social participation. We don’t know if it will work but it does, it would greatly enhance our ability to collect some long term outcomes in our patients. | ||||||||||||||||
| Sequist | Tom | MD | MGB | Chief Patient Experience and Equity Officer | Professor | Patient Experience Healthcare Equity, Quality and Safety | Tom Sequist, MD, MPH, is the Chief Patient Experience and Equity Officer at Mass General Brigham. He leads system-wide strategies for improving patient experience and health care equity, while also overseeing quality and safety. He is a practicing general internist at Brigham and Women’s Hospital and is a Professor of Medicine and Professor of Health Care Policy at Harvard Medical School. Sequist graduated from Cornell University with a bachelor’s degree in chemical engineering. He received his MD from Harvard Medical School, and his MPH from the Harvard School of Public Health. Previous to his current role, he served as the Chief Quality and Safety Officer at Partners Healthcare, and also as the Director of Research and Clinical Program Evaluation for Harvard Vanguard Medical Associates and Atrius Health. Sequist’s research interests include health care equity, ambulatory quality measurement and improvement, patient and provider education, and the innovative use of health information technology. Sequist is particularly interested in health policy issues affecting care for Native Americans and has worked collaboratively with the Indian Health Service to evaluate the provision of care for this population. Sequist is a member of the Taos Pueblo tribe in New Mexico and is committed to improving Native American health care, serving as the Director of the Four Directions Summer Research Program at Harvard Medical School and the Medical Director of the Brigham and Women’s Hospital Physician Outreach Program with the Indian Health Service. | Dr. Sequist is the Mass General Brigham Chief Patient Experience and Equity Officer, and in this role oversees quality, safety, patient experience, equity, and community health; as well as medical affairs functions including pharmacy and clinical credentialing. I have significant experience in designing new systems to improve care via health information technology and digital programs, patient engagement, and provider incentives; all informed by innovative data analytics. I am passionate about health care equity and the potential for implementing entirely new solutions to solve issues around access to digital care, community-based and mobile care, language barriers, and addressing upstream challenges such as food and housing insecurity. | |||||||||||||||||
| Shenoy | Erica | MD, PhD | MGH | Associate Chief, Infection Control Unit | Assistant Professor | Infectious Disease | Infectious Diseases Emerging Infections Clinical Decision Support Healthcare Economics | Erica Shenoy, MD, PhD, is an infectious diseases physician at Massachusetts General Hospital (MGH) where she is Associate Chief of the Infection Control Unit. She is an Assistant Professor of Medicine at Harvard Medical School and is trained as a health economist. Her research has evaluated the clinical, operational and economic impact of competing infection control strategies for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) through clinical studies and mathematical modeling, has leveraged electronic health records for infection control surveillance, and applied machine-learning techniques to create risk prediction models for Clostridioides difficile infection. She has investigated and published on detection and prevention of nosocomial infections. Shenoy is Medical Director of the Regional Emerging Special Pathogens Treatment Center at MGH, one of 10 facilities supported by the US Department of Health and Human Services as part of the regional treatment network for emerging pathogens. She has served as the Infectious Diseases and Infection Control advisor to MGH and Mass General Brigham for the COVID-19 response. She has published and lectured nationally and internationally on infection prevention approaches for SARS-CoV-2, the role of universal masking in healthcare settings and in the community, evaluation and management of healthcare workers infected with COVID-19, and on optimizing evaluation and isolation of patients with suspected and confirmed COVID-19 in healthcare settings. Shenoy is a Fellow in both the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). She has served on the Guidelines Committee of SHEA and currently a member of SHEA’s Public Policy and Government Affairs Committee and co-chair of the Sterilization and High-Level Disinfection guidelines committee. An active member of IDSA, she previously served on the IDSA Antimicrobial Resistance Committee. | Using innovative technologies and methods that leverage the electronic health record to improve patient care and healthcare operations. | ||||||||||||||||
| Slaugenhaupt | Susan | PhD | MGH | Scientific Director, Mass General Research Institute | Professor | Neurology | Genes and Disease Research Management Science Communication | Susan A. Slaugenhaupt, PhD is a Professor of Neurology (Genetics) at Mass General Hospital/Harvard Medical School, the Scientific Director of the Mass General Research Institute and an Investigator in the Center for Genomic Medicine at Mass General. She is a human geneticist whose work focuses on two neurologic disorders, familial dysautonomia (FD) and mucolipidosis type IV (MLIV), as well as the common cardiac disorder mitral valve prolapse (MVP). Discoveries in the Slaugenhaupt Lab have led to the successful implementation of critical population screening for FD and MLIV, the identification of genes for familial MVP, and more recently to the development of therapeutics for FD and MLIV. Slaugenhaupt also spearheads several programs and educational initiatives at Mass General, including a thriving undergraduate summer internship program. Her Research Institute team works to promote science at Mass General by increasing interactions with industry, by fundraising for Research Institute initiatives, and by promoting Mass General research to both internal and external audiences. In 2013, Slaugenhaupt was named the Elizabeth G. Riley and Daniel E. Smith, Jr. MGH Research Scholar. In 2016, she was honored with a prestigious Javits Neuroscience Investigator Award by the National Institute for Neurological Disorders and Stroke (NINDS), and in 2016 she was named one of the Top Ten Women to Watch in Science and Technology by the Boston Business Journal. She was elected to the Board of the American Society of Human Genetics in 2018 and she serves on the Board of Trustees at Eckerd College. She was recently named the Elizabeth G. Riley and Daniel E. Smith Jr. Endowed MGH Research Institute Chair. | |||||||||||||||||
| Sloan | Deb | MGB | Senior VP, Treasury | Finance | Financial Analysis Finance Operations Advanced Financial Management | Debra Sloan is a transaction-focused corporate finance professional with extensive experience in the healthcare sector. She is recognized as a conceptual strategic thinker with a proven ability to integrate complex credit considerations and financial analysis with specialized industry expertise to achieve targeted results. Her experience encompasses the structuring & execution of financing transactions, credit analysis, investor relations, corporate acquisitions, due diligence, risk assessment & management, and financial planning. Sloan has been with Mass General Brigham (f/k/a Partners HealthCare) since 1994. As VP, Treasury (since 2013), she is responsible for ensuring that the organization has adequate capital and liquidity to achieve its strategic, financial and operational targets and for leading various strategic initiatives, including acquisitions and strategic investments. She also has managerial oversight for core Treasury functions, including capital markets activities, investor & bank relationships, cash management & commercial banking, insurance risk financing programs and overall balance sheet risk management. Sloan has structured and led more than $20 billion in debt financings and executed more than $1.5 billion interest rate swaps on behalf of Mass General Brigham. Sloan received her BS in computer science and economics from Union College and is a Chartered Financial Analyst. She recently joined the Finance Committee for Controlled Risk Insurance Company (CRICO), the insurance program for Harvard medical institutions and their affiliates, and the adjunct faculty at Harvard Medical School where she will Co-direct a course in Advanced Financial Management in Healthcare Organizations (Master in Clinical Service Operations) in the fall of 2021. Sloan also sits on the Investment Committee for the Health Care Financial Management Association and the Board of Advisors for Women in Public Finance, Boston Chapter. She is also a member of the Boston Security Analysts Society and the National Federation of Municipal Analysts. She served as a Board & Finance Committee member of Aviv Centers for Living (skilled nursing facility & rehabilitation care provider) from 2010-2013. | As VP, Treasury, a position which I have held since 2013, I am responsible for ensuring that Mass General Brigham has adequate capital and liquidity to achieve its strategic, financial and operational targets. I also oversee capital markets activities, investor & bank relationships, cash management, insurance risk financing programs and overall balance sheet risk management. In sum, my focus is largely to manage, maintain and promote the financial stability of our organization, reporting to the Chief Financial Officer. An area of innovation about which I am most passionate is the implementation of private debt placements within the non-profit healthcare sector. In more simple terms, non-profit borrowers, such as MGB, typically raise capital via the public debt markets, relying on investment banks to structure and underwrite their financing transactions. As part of this process, banks help to identify and market the bonds to investors. They receive a negotiated fee for each bond sold. By shifting to a private placement model, I have eliminated the role of the investment bank and its associated fees, resulting in significant savings, while also reducing the time to complete a transaction from roughly 6 months to roughly 6 weeks. By leveraging relationships which I have cultivated with a select group of prominent institutional investors over many years, I have been able to establish a de facto MGB lender group to participate in a series of private placements, beginning in 2012, and aggregating to a cumulative total of $1.5 billion, which is approximately 25% of MGB’s total debt, resulting in over $45 million in value to MGB. This innovation in raising capital in the non-profit healthcare sector has since been replicated by numerous other healthcare borrowers. | ||||||||||||||||||
| Smith | Barbara | MD, PhD | MGH | Director, Breast Program and Co-Director of the Women's Cancer Program | Associate Professor | Surgical Oncology | Surgical Oncology Breast Cancer Image-guided Interventions | Barbara L. Smith, MD, PhD, is a graduate of MIT, the Harvard-MIT Division of Health Sciences and Technology and the Harvard Graduate School pf Arts and Sciences. She is the Director of the Breast Program at Massachusetts General Hospital and a member of the Division of Surgical Oncology at MGH. She is a Professor of Surgery at Harvard Medical School and holds the MGH Trustees Chair in Breast Surgery. Smith has an active breast surgical oncology practice and studies innovative surgical techniques. She leads a series of multicenter NIH-funded trials assessing a protease-activated fluorescent agent and detection device for intraoperative margin assessment in breast cancer surgery. | |||||||||||||||||
| Stanford | Fatima | MD | MGH | Director of Diversity, Nutrition Obesity Research Center at Harvard (NORCH); Equity Director, Endocrine Division and Director, Anti-Racism Initiatives, Neuroendocrine Unit, MGH | Dr. Stanford practices and teaches at Massachusetts General Hospital (MGH)/ Harvard Medical School (HMS) as one of the first fellowship-trained obesity medicine physicians in the world. Dr. Stanford received her BS and MPH from Emory University as a MLK Scholar, her MD from the Medical College of Georgia School of Medicine as a Stoney Scholar, her MPA from the Harvard Kennedy School of Government as a Zuckerman Fellow in the Harvard Center for Public Leadership, and her executive MBA as a merit-based scholarship recipient from the Quantic School of Business and Technology. She completed her Obesity Medicine & Nutrition Fellowship at MGH/HMS after completing her internal medicine and pediatrics residency at the University of South Carolina. She has served as a health communications fellow at the Centers for Disease Control and Prevention and as a behavioral sciences intern at the American Cancer Society. Upon completion of her MPH, she received the Gold Congressional Award, the highest honor that Congress bestows upon America’s youth. Dr. Stanford has completed a medicine and media internship at the Discovery Channel. An American Medical Association (AMA) Foundation Leadership Award recipient in 2005, an AMA Paul Ambrose Award for national leadership among resident physicians in 2009, she was selected for the AMA Inspirational Physician Award in 2015. The American College of Physicians (ACP) selected her as the 2013 recipient of the Joseph E. Johnson Leadership Award and the Massachusetts ACP selected her for the Young Leadership Award in 2015. She is the 2017 recipient of the HMS Amos Diversity Award and Massachusetts Medical Society (MMS) Award for Women’s Health. In 2019, she was selected as the Suffolk District Community Clinician of the Year and for the Reducing Health Disparities Award for MMS. She was selected for The Obesity Society Clinician of the Year in 2020. In 2021, she has been awarded the MMS Grant Rodkey Award for her dedication to medical students and the AMA Dr. Edmond and Rima Cabbabe Dedication to the Profession Award which recognizes a physician who demonstrates active and productive improvement to the profession of medicine through community service, advocacy, leadership, teaching, or philanthropy. She is the 2021 Recipient of the Emory Rollins School of Public Health Distinguished Alumni Award. | ||||||||||||||||||||
| Taveras | Elsie | MD, MPH | MGB | Chief Community Health Equity Officer | Elsie M. Taveras, M.D., M.P.H. is the inaugural Chief Community Health Equity Officer at Mass General Brigham. She is also Executive Director of the Kraft Center for Community Health at Mass General Hospital and the Conrad Taff Endowed Professor of Pediatrics and Nutrition at Harvard Medical School. Dr. Taveras works collaboratively with leader s from across the system to lead Mass General Brigham forward as a force for change in confronting inequity and racism. She leads MGB’s efforts of United Against Racism focused on patient care and health equity, as well as the new system wide strategy in community health; all with a focus on demonstrable outcomes. Dr. Taveras is a board-certified Pediatrician, clinical epidemiologist, and a community health services researcher. Her main focus of research is understanding determinants of chronic diseases in women and children and developing interventions across the lifecourse to prevent obesity and chronic diseases, especially in underserved populations. Her work spans the spectrum of observational studies and interventions—to identify and quantify risk factors— and to modify these risk factors for health promotion and disease prevention. Dr. Taveras’ leadership, passion and expertise has been recognized widely. In 2016, she received the Public Health Leadership in Medicine Award from the Massachusetts Association of Public Health for her extensive work improving health and health care in community-based settings. In 2017, she was promoted to Professor of Pediatrics becoming the first Latina at Harvard Medical School to reach that rank in Pediatrics. In 2018, she received the Conrad Taff Endowed Chair at Harvard Medical School, becoming the first Latina to hold an Endowed Professorship across Harvard Medical School and at Massachusetts General Hospital. She has more than 250 publications and has received continuous research funding from the National Institutes of Health, the Centers for Disease Control and Prevention, the Patient-Centered Outcomes Research Institute, the American Diabetes Association, the Robert Wood Johnson Foundation, the Boston Foundation, among many other federal and foundation sources. | Dr. Taveras is the Mass General Brigham Chief Community Health Equity Officer, and in this role, I oversee MGB system efforts of United Against Racism focused on patient care and health equity, and our new system wide strategy in community health; all with a focus on demonstrable outcomes. I have extensive experience designing and implementing evidence-based programs in both clinical and community settings. My passion is developing clinical-community programs that improve the health of children and families while reducing health disparities. I have focused my career on developing and testing programs across the lifecourse to prevent poor health outcomes, especially in underserved population. As Chief Community Health Equity Officer, I work collaboratively with leaders from across the system to lead Mass General Brigham forward as a force for change in confronting inequity and racism. | |||||||||||||||||||
| Wiggs | Janey | MD, PhD | MEE | Associate Chief, Ophthalmology Clinical Research | Professor | Opthalmology | Genes and Disease Ocular Disorders Genetic Testing Gene-based Therapies | Janey Wiggs, MD, PhD, is a clinician-scientist with a research focus in ocular genetics. Her laboratory is a leader in glaucoma genetics and she has been elected to the National Academy of Medicine for her research and achievements in the field of ocular genetics, including the discovery of multiple genetic and environmental risk factors for glaucoma, and for developing and implementing genetic testing for inherited eye disease. | I am the Associate Chief for clinical Research in Ophthalmology at the Mass Eye and Ear and the Vice Chair for Clinical Research in Ophthalmology at Harvard Medical School. I am also the director of the CLIA-certified genetic testing laboratory for inherited eye diseases and a co-director of the Ocular Genomics Institute at Mass Eye and Ear. I am a clinician scientist and see patients in the glaucoma service at MEE. My research is focused on the genetics of glaucoma and I have received NIH funding for this work for nearly 30 years. I am absolutely passionate about the translation of genetic information to clinical practice specifically using genetic risk variants to identify patients with high disease risk as well as develop novel gene-based therapies targeting disease-related genes. | ||||||||||||||||
| Moran | Jane | MBA | MGB | Chief Information and Digital Officer | Jane Moran is Chief Information and Digital Officer for Mass General Brigham. Named in the role in September 2021, Jane leads the development, deployment, and efficient operations of technology across the organization. Accelerating Mass General Brigham’s overall technology and digital strategy, Jane is focused on delivering digital health capabilities enhancing the equity and efficiency of healthcare delivery and helping to make medicine more personalized and precise. Prior to this, Jane served as Unilever’s Chief Information Officer and Chief Technology Advisor for nearly seven years. Jane’s passion for technology comes from her roots as a developer. At the beginning of her career, Jane built financial portfolio management and trading software applications. She was an IT consultant to Fortune 500 companies for many years which included implementing large scale ERP and CRM platforms. She has held CIO/CTO posts for the past 20 years, and prior to her experience with Unilever, she was Group CIO at Thomson Reuters. Jane was recognized as the first woman to top Computer Weekly’s ranking of the 100 most influential people in technology. Outside of Unilever Jane is a very active member of the global technology community. She also holds two non-executive director positions with JP Morgan, JP Morgan Securities PLC and JP Morgan Europe Limited. | ||||||||||||||||||||
| Goodman | Elaine Besancon | MD | MGH | Director, Medical Walk-In Unit | Instructor | Internal Medicine Clinical Informatics | Health Information Technology Digital Health Clinical Operations Entrepreneurship Clinical Decision Support Population Health Management Artificial Intelligence Care Delivery Model Innovation | Dr. Goodman is a practicing physician at Massachusetts General Hospital who is board certified in Internal Medicine and Clinical Informatics. She received her MD from Harvard Medical School and her MBA from Harvard Business School. She has worked in health technology across many settings including academic centers, health IT start-ups, venture capital investing, pharmaceutical companies, payors, and providers. She is passionate about democratizing access to technology for all patients and addressing technology’s contribution to clinician burnout. Dr. Goodman currently serves as the Clinical Lead for Population Health Management on the Mass General Brigham Digital team, as well as the Mass General Brigham Venture Fellow where she is a member of the AI and Digital Innovation Fund leadership team. She continues to advise startups as an expert mentor for the Harvard Innovation Lab as well as providing mentorship via the Stanford Masters in Clinical Informatics Management program. She previously served as the Associate Chief Medical Officer for the healthcare IT startup Wellframe, where she helped lead the company from the seed stage through Series C funding. She also worked as the Director of the Massachusetts General Hospital COVID clinic as well as the Director of Urgent Care and After-Hours Innovation for the Division of Primary Care. | |||||||||||||||||
| Pierre | Claire-Cecile | MD | BWH | Associate chief medical officer (ACMO) and Vice President of Community Health | Instructor | Internal Medicine | Clinical Informatics, Population Health, Value Based Contract, Community Based Care, Public Private Partnerships, Entrepreneurship, Leadership Coaching, Global Health | Dr. Claire-Cecile Pierre is the Associate Chief Medical Officer and Vice President of Community Health at the Brigham and Women’s Hospital. Trained in Internal Medicine at the Cambridge Health Alliance and Board Certified in Clinical Informatics, Dr. Pierre holds decades of experience in the use of technology to improve the quality of care. With a career focused on health equity, Dr. Pierre seeks to encourage healthcare innovations that appropriately center and value the expertise of patients and communities. Dr. Pierre has held leadership roles in community health centers across Massachusetts supporting the implementation of value based contracts and ensuring patient centered approaches to care. She also holds decades of experience in global health focusing on health systems strengthening after disasters. She has responded to multiple outbreaks, including HIV, Cholera, Zika and COVID 19. She has worked at Partners in Health, the World Bank and Babson College in roles that lead to impactful collaborations across policy makers, academia, and private sector partners. She is an instructor in medicine at Harvard Medical School | With over two decades of experience in informatics, community health and health equity and my lived experience as thrice displaced person, I am ready to contribute to the design, strategy and performance of funds and ventures that would like to analyze their work through an equity lens. I can also draw on my experience as a leadership coach to support executive and founding teams to increase their impact | ||||||||||||||||
| Cooper | Zara | MD, MSc, FACS | BWH | Kessler Director for the Center for Surgery and Public Health Founder and Co-Director of the Center for Geriatric Surgery | Professor | Surgery | Palliative Care Serious Illness Trauma Surgery Surgical Critical Care Patient outcomes Quality and safety Geriatric trauma Geriatric Surgery Health Services Research Diversity Equity and Inclusion | Dr. Cooper, MD, MSc, FACS, is a Professor at Harvard University and an acute care surgeon, trauma surgeon and surgical intensivist at Brigham and Women’s Hospital where she serves as Kessler Director for the Center for Surgery and Public Health, Founder and Co-Director of the Center for Geriatric Surgery, and holds the Michele and Howard J. Kessler Distinguished Chair in Surgery and Public Health. Cooper is an internationally recognized health services researcher and clinical innovator with a focus on using principles of geriatric medicine and palliative care to improve surgical outcomes and experience for patients and their families. She currently serves on the American College of Surgeons (ACS) Geriatric Surgical Verification Committee, ACS Geriatric Task Force, and is co-chair of the Board of Trustees Committee on Diversity, Equity, Inclusion and Community Health at Brigham and Women’s Hospital. In 2021, Cooper received the Brigham and Women’s Physicians Organization Pillar Award for Diversity and Inclusion and the Richard E. Wilson Award in recognition of her excellence in surgical residence education. She has published over 160 peer-reviewed manuscripts and lectures internationally on topics related to geriatric trauma, palliative care, and equity in surgery. | I am a clinical innovator internationally recognized for my clinical expertise, research, and educational contributions at the intersection of surgery, geriatrics, and palliative care. The overarching goal of my research is to integrate palliative care and geriatrics into routine surgical care for seriously ill and older surgical patients to improve surgical outcomes and experience for patients and their families. I am a leader in several national academic societies which I leverage to advance social justice, equity and inclusion for patients and surgeons alike. I also lecture internationally on topics related to geriatric trauma, palliative care, and equity in surgery. | ||||||||||||||||
| Prestipino | Anna | MGH/MGPO | Executive Emeritus | Operations | Clinical Operations Strategy Crisis management New program development and implementation | Ann is an executive emeritus of the Massachusetts General Hospital and the Massachusetts Physician Organization (MGH/MGPO). She has overseen a wide variety of clinical/academic departments as well as leading the development of the institution’s centers of excellence. This included oversight of the administrative and operational aspects of the clinical, educational, research and community service of these areas. She has had financial responsibility for approximately $1B. Ann was instrumental in the development of the Center for Disaster Medicine at the MGH/MGPO. She has served as Incident Commander leading MGH/MGPO’s response to major disasters including the Boston Marathon Bombing and Covid. She has played a leadership role overseeing all aspects of the institution’s educational mission. Ann has spent her career at these organizations, serving in roles of increasing responsibility as well as assisting at Mass General Brigham in several strategic initiatives. | My career focus has been in clinical operations and strategy including the acquisition and integration of new hospitals into the MGB system. Work in the development of new delivery models of care through center development and integration of new medical devices and biotechnology has been, and continues to be, an area of great interest and most importantly value to our patients. |